- Home
- KFS vs PROK Comparison
KFS vs PROK Comparison
Compare KFS & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KFS
- PROK
- Stock Information
- Founded
- KFS 1989
- PROK 2015
- Country
- KFS United States
- PROK United States
- Employees
- KFS N/A
- PROK N/A
- Industry
- KFS Property-Casualty Insurers
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KFS Finance
- PROK Health Care
- Exchange
- KFS Nasdaq
- PROK Nasdaq
- Market Cap
- KFS 396.0M
- PROK 384.2M
- IPO Year
- KFS 1996
- PROK N/A
- Fundamental
- Price
- KFS $14.36
- PROK $2.48
- Analyst Decision
- KFS
- PROK Buy
- Analyst Count
- KFS 0
- PROK 5
- Target Price
- KFS N/A
- PROK $6.25
- AVG Volume (30 Days)
- KFS 68.8K
- PROK 2.4M
- Earning Date
- KFS 08-07-2025
- PROK 08-12-2025
- Dividend Yield
- KFS N/A
- PROK N/A
- EPS Growth
- KFS N/A
- PROK N/A
- EPS
- KFS N/A
- PROK N/A
- Revenue
- KFS $119,287,000.00
- PROK $527,000.00
- Revenue This Year
- KFS N/A
- PROK $265.05
- Revenue Next Year
- KFS N/A
- PROK N/A
- P/E Ratio
- KFS N/A
- PROK N/A
- Revenue Growth
- KFS 12.05
- PROK N/A
- 52 Week Low
- KFS $7.06
- PROK $0.46
- 52 Week High
- KFS $16.80
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- KFS 52.21
- PROK 49.64
- Support Level
- KFS $13.96
- PROK $2.30
- Resistance Level
- KFS $14.36
- PROK $2.53
- Average True Range (ATR)
- KFS 0.41
- PROK 0.19
- MACD
- KFS 0.02
- PROK -0.02
- Stochastic Oscillator
- KFS 83.62
- PROK 74.44
About KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.